NCT04243863已完成1 期
A Randomized, Double Blind, Placebo-Controlled, Sequential Group, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-7145 in Healthy Adult Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 83
- 试验地点
- 1
- 主要终点
- Part 1: Number of subjects with adverse events
研究概览
简要总结
This is a 2-part, first-in-human dose-ranging study to evaluate the safety and pharmacokinetics of escalating doses of VNRX-7145. In part 1, subjects will receive a single dose of VNRX-7145; in part 2 subjects will receive multiple doses of VNRX-7145 for 10 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults 18-45 years
- •Males or non-pregnant, non-lactating females
- •Body mass index (BMI): ≥18.5 kg/m² and ≤32.0 kg/m²
- •Normal blood pressure
- •Normal laboratory tests
排除标准
- •Current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, autoimmune, hematologic, neoplastic, or neurological disorder
- •History of drug allergy
- •Abnormal ECG or history of clinically significant abnormal rhythm disorder
- •Positive alcohol, drug, or tobacco use/test
研究组 & 干预措施
VNRX-7145
Experimental
Oral dosing
干预措施: VNRX-7145 (Drug)
Placebo
Placebo Comparator
Oral dosing
干预措施: Placebo (Drug)
结局指标
主要结局
Part 1: Number of subjects with adverse events
时间窗: Day 8
Part 2: Number of subjects with adverse events
时间窗: Day 17
次要结局
- Part 1: AUC0-tau(Days 1-3)
- Part 1: Cmax(Days 1-3)
- Part 1: tmax(Days 1-3)
- Part 1: CLr(Days 1-3)
- Part 2: AUC0-tau(Days 1-10)
- Part 2: Cmax(Days 1-10)
- Part 2: tmax(Days 1-10)
- Part 2: CLr(Days 1-10)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430Filovirus InfectionsEbola Virus InfectionNCT02319772BioCryst Pharmaceuticals94
已完成
1 期
COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy VolunteersCoronavirusNCT04392219Ridgeback Biotherapeutics, LP130
终止
1 期
A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult VolunteersAcromegalyNCT03571594Ono Pharmaceutical Co. Ltd76
已完成
1 期
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy ParticipantsMultiple SclerosisNCT05131971GlaxoSmithKline54
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis PatientsRheumatoid ArthritisNCT02089087Novartis Pharmaceuticals75